Regenerative medicine: clinical trials launched for the treatment of delayed union fractures

50% of fractures do not heal alone and require surgical bone grafting; this figure equates to around one million patients in Europe. The REBORNE project (Regenerating Bone Defects using New biomedical Engineering approaches), funded by the European Commission and coordinated by Inserm, has just received the green light from the French Medicinal Agency ANSM to begin orthopaedic surgery clinical trials. The clinical trials aim to repair bones using adult stem cells combined with biomaterials. It will be conducted in France in the Créteil University Hospital Centre and the Regional University Hospital Centre in Tours, in collaboration with the French Blood Establishment.

The REBORNE project began three years ago and its originality lies in using mesenchymal stem cells (MSC), found in bone marrow, to help heal fractures. Adult stem cells are amplified in culture, then are associated with biomaterial before being implanted on the fracture. Promising pre-clinical trials have now paved the way for the launch of these new clinical trials.

Following trauma (fall or road accident), there is a high incidence of delayed union or non-union in tibia, femur or humerus bones requiring a surgical apposition of an autologous bone graft (patient’s own bone). However, the bone graft available is limited and complications are often observed at the second surgical site.

The partners of the European project REBORNE propose an alternative treatment using autologous mesenchymal stem cells associated with a synthetic bone substitute.
Thanks to a bone marrow aspiration under local anaesthesia, the mesenchymal stem cells are isolated and amplified in culture for 21 days. During the surgical intervention stem cells are associated with biphasic calcium phosphate ceramic granules and implanted at the site of the fracture. In this way, the biomaterial is used as “scaffolding” and encourages stem cell proliferation. The stem cells are then differentiated into bone cells and regenerate the bone tissue around the fracture.

Bone formation (in green) and bone marrow formation (in red) further to a mixture of human stem cells and biomaterial granules (grey/white) being implanted at a subcutaneous site in nude mice. This histological section shows osteoinduction by the cell/biomaterial mix with the formation of around 41% of bone tissue four weeks after implantation.

The French Medicinal Agency ANSM gave its green light on 3 January 2013 so that these Inserm-sponsored trials can now begin in France, with seven patients receiving treatment in the Créteil University Hospital Centre and the Regional University Hospital Centre in Tours. Ultimately, thirty patients will be included in France, Spain, Germany and Italy to be part of this multi-centre European study.

“The objective of this trial is to show that biomaterials and stem cells are safe and are at least equivalent to standard treatments, without their disadvantages. This surgery is less invasive and preserves the patients’ bone stock. For these reasons, it is preferable to bone grafts in terms of triggering bone healing” explains Pierre Layrolle, director of Research, Inserm and coordinator of REBORNE.

Research contacts

Pierre LAYROLLE  
Coordinator of REBORNE,  
Director of Research, Inserm U957  
Faculty of Medicine, University of Nantes  
+33 (0)2 72 64 11 43  
pierre.layrolle@inserm.fr

Luc SENSEBE  
Co-coordinator  
Medical and Scientific Director  
EFS Pyrénées Méditerranée - Toulouse  
+33 (0)5 61 28 37 60  
luc.sensebe@efs.sante.fr

Press Contact  
presse@inserm.fr
For further information:

**Reborne**

Regenerating Bone Defects using New biomedical Engineering approaches

The objective of REBORNE is to develop new biomaterials that stimulate bone tissue formation with a view to correcting bone regeneration defects in orthopaedic and maxillofacial surgery. Biomaterials, combined with the use of stem cells, are interesting alternatives to biological grafts.

http://www.reborne.org/

The REBORNE project kicked-off in January 2010 and will run for five years using an overall budget of roughly 12 million Euros provided by the European Union (PC7). The project involves 24 partners, based in eight European countries: http://www.reborne.org/presentation.html

**Inserm** www.inserm.fr

Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute that operates under the joint authority of the French Ministry of Health and French Ministry of Research.

Its researchers are tasked with studying all diseases, from the most common to the most rare, through their work in biological, medical and public health research.

With a budget of 905 million Euros in 2011, Inserm supports more than 300 laboratories across France. More than 13,000 researchers, engineers, technicians and administrators are grouped together in the various teams.

Inserm is a member of the Alliance nationale pour les sciences de la vie et de la santé (French National Alliance for Life and Health Sciences), founded in April 2009 with CNRS, Inserm, the CEA, INRA, INRIA, the IRD, the Pasteur Institute, the Conference of University Presidents (CPU) and the Conference of Chairman of the Regional and University Hospital Centres. This alliance is part of the policy to reform the research system, with the aim of better coordinating the roles of the various stakeholders and enhancing the position of French research in this sector through a concerted programme.

Inserm is the leading sponsor of European ‘Health’ projects, with 28 projects coordinated by the Institute within the framework of PC7.